Abstract
The number of pertinent researches of COVID-19 has increased rapidly but they mainly focused on the description of general information of patients with confirmed infection. We aimed to bridge the gap between disease classification and clinical outcome in intensive care patients, data of which are scarce and such classification could help in individual evaluation and provide effective triage for treatment and management. Specifically, we collected and filtered out 151 intensive care patients with complete medical records from Tongji hospital in Wuhan, China. We constructed a fully Bayesian latent variable model for integrative clustering of six data categories, including demographic information, symptoms, original comorbidities, vital signs, blood routine tests and inflammatory marker measurements. We identified four prognostic types of COVID-19 in intensive care patients, presenting a stepwise distribution in age, respiratory condition and inflammatory markers, suggesting the prognostic efficacy of these indicators. This report, to our knowledge, is the first attempt of dealing with classification of COVID-19 in intensive care patients. We acknowledge the limitation of ignoring the effect of treatment, but we believe such classification is enlightening for better triage, allowing for a more rational allocation of scarce medical resources in a resource constrained environment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Key R&D Program of China (2019YFC1711000), the National Natural Science Foundation of China (81973145), the "Double First-Class" University Project (CPU2018GY09), the China Postdoctoral Science Foundation (2019M651805), the Science Foundation of Jiangsu Commission of Health (H2018117), and the Emergency Project for the Prevention and Control of the Novel Coronavirus Outbreak in Suzhou (SYS2020012).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding This work was supported by the National Key R&D Program of China (2019YFC1711000), the National Natural Science Foundation of China (81973145), the “Double First-Class” University Project (CPU2018GY09), the China Postdoctoral Science Foundation (2019M651805), the Science Foundation of Jiangsu Commission of Health (H2018117), and the Emergency Project for the Prevention and Control of the Novel Coronavirus Outbreak in Suzhou (SYS2020012).
Conceptualization: X. Lu.
Acquisition, analysis, or interpretation of data: J. Wang, Y. Wang, X. Lu, T. Chen.
Statistical analysis: X. Lu, F. Yan.
Investigation: X. Lu, T. Chen, Y. Wang, Y. Li.
Drafting of the manuscript editing: X. Lu, T. Chen, Y. Wang.
Funding acquisition: J. Wang, F. Yan.
Supervision: J. Wang, F. Yan.
Data availability Dr J. Wang had full access to all of the data in the study. After publication, the data will be made available to others on reasonable requests after approval from the author (J.W, dr_wangjun{at}suda.edu.cn) and Wuhan Tongji Hospital (Y.L, dr_ysli{at}126.com).
Data Availability
Dr J. Wang had full access to all of the data in the study. After publication, the data will be made available to others on reasonable requests after approval from the author (J.W, dr_wangjun@suda.edu.cn) and Wuhan Tongji Hospital (Y.L, dr_ysli@126.com).
